AR022116A1 - COMBINATION THERAPY FOR RHCAVIRINE INDUCTION HCV - INTERFERON ALFA - Google Patents

COMBINATION THERAPY FOR RHCAVIRINE INDUCTION HCV - INTERFERON ALFA

Info

Publication number
AR022116A1
AR022116A1 ARP990106463A ARP990106463A AR022116A1 AR 022116 A1 AR022116 A1 AR 022116A1 AR P990106463 A ARP990106463 A AR P990106463A AR P990106463 A ARP990106463 A AR P990106463A AR 022116 A1 AR022116 A1 AR 022116A1
Authority
AR
Argentina
Prior art keywords
hcv
effective amount
interferon alfa
ribavirin
weeks
Prior art date
Application number
ARP990106463A
Other languages
Spanish (es)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR022116A1 publication Critical patent/AR022116A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se revela el uso de ribavirina e interferon alfa para la manufactura de composiciones farmacéuticas para tratar un paciente con infeccion cronica dehepatitis C, por ejemplo un paciente que tiene el genotipo 1, 2 o 3 de VHC, para erradicar el ARN delVHC detectable, mediante un método que comprende laadministracion de una cantidad efectiva de ribavirina en asociacion con una cantidad efectiva de interferon alfa, que se caracteriza porque el tratamiento delos pacientes que tienen infeccionescroni cas de hepatitis C se efectua en dos períodos de tratamiento; (a) un primer período de tratamiento de al menos 20 a30 semanas, en el cual se administran una cantidad terapéuticamente efectiva de ribavirina y una cantidad dosificante deinduccion tera péuticamente efectiva deinterferon alfa, suficiente al menos para disminuir sustancialmente, y preferentemente para erradicar el ARN del VHC detectable; y b) un segundo período detratamiento de al menos de 20 a 30 semanas, donde unacantidad terapéut icamente efectiva de ribavirina y una cantidad terapéuticamente efectiva de interferonalfa se administran en forma suficiente para mantener el ARN del VHC no detectable, durante al menos de 20 a 30 semanas luego de finalizar elprimer períodode tra tamiento y para mantener el ARN del VHC no detectable durante al menos 24 semanas, luego de finalizar el segundo período de tratamiento.The use of ribavirin and interferon alfa is revealed for the manufacture of pharmaceutical compositions to treat a patient with chronic hepatitis C infection, for example a patient who has HCV genotype 1, 2 or 3, to eradicate detectable HCV RNA, by a method comprising the administration of an effective amount of ribavirin in association with an effective amount of interferon alfa, which is characterized in that the treatment of patients who have chronic hepatitis C infections is carried out in two treatment periods; (a) a first treatment period of at least 20 to 30 weeks, in which a therapeutically effective amount of ribavirin and a dosage amount of therapeutically effective therapeutic interference of interferon alfa are administered, sufficient at least to substantially decrease, and preferably to eradicate RNA HCV detectable; and b) a second treatment period of at least 20 to 30 weeks, where a therapeutically effective amount of ribavirin and a therapeutically effective amount of interferonfa are administered sufficiently to keep HCV RNA undetectable, for at least 20 to 30 weeks after the end of the first treatment period and to keep HCV RNA undetectable for at least 24 weeks, after the end of the second treatment period.

ARP990106463A 1998-12-18 1999-12-16 COMBINATION THERAPY FOR RHCAVIRINE INDUCTION HCV - INTERFERON ALFA AR022116A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21587598A 1998-12-18 1998-12-18

Publications (1)

Publication Number Publication Date
AR022116A1 true AR022116A1 (en) 2002-09-04

Family

ID=22804763

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990106463A AR022116A1 (en) 1998-12-18 1999-12-16 COMBINATION THERAPY FOR RHCAVIRINE INDUCTION HCV - INTERFERON ALFA

Country Status (4)

Country Link
AR (1) AR022116A1 (en)
AU (1) AU2156900A (en)
PE (1) PE20001386A1 (en)
WO (1) WO2000037097A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7179791B2 (en) 2001-01-11 2007-02-20 Duke University Inhibiting GS-FDH to modulate NO bioactivity
US8183005B1 (en) 2004-08-11 2012-05-22 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical agents for treating HCV infections
US7723310B2 (en) 2004-10-18 2010-05-25 Three Rivers Pharmaceuticals, Llc Large dose ribavirin formulations
WO2007132882A1 (en) * 2006-05-16 2007-11-22 Tokyo Metropolitan Organization For Medical Research Pharmaceutical composition for treating or preventing hcv infection
EP1977759A1 (en) * 2007-03-27 2008-10-08 4Sc Ag Pharmaceutical composition comprising a cytokine
CA2682050A1 (en) * 2007-03-27 2008-10-02 4Sc Ag Pharmaceutical composition comprising a cytokine
US20110270212A1 (en) * 2007-10-05 2011-11-03 Medtronic, Inc. Pharmacokinetic control for optimized interferon delivery
WO2010061881A1 (en) 2008-11-26 2010-06-03 中外製薬株式会社 Oligoribonucleotide or peptide nucleic acid capable of inhibiting activity of hepatitis c virus
CA2811250C (en) 2011-10-21 2015-08-11 Abbvie Inc. Methods for treating hcv
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
GB2506086A (en) 2011-10-21 2014-03-19 Abbvie Inc Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
DE69801970T2 (en) * 1997-09-21 2002-06-13 Schering Corp., Kenilworth Combination therapy for the removal of detectable HCV-RNA in patients with chronic hepatitis C infection

Also Published As

Publication number Publication date
WO2000037097A1 (en) 2000-06-29
PE20001386A1 (en) 2000-12-14
AU2156900A (en) 2000-07-12

Similar Documents

Publication Publication Date Title
AR021876A1 (en) COMBINATION THERAPY FOR HCV INDUCTION OF RIBAVIRINA - INTERFERON ALFA PEGILADO
AR019551A1 (en) USE OF RIBAVIRINE IN COMBINATION WITH INTERFERON ALFA FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR COMBINATION THERAPY TO ERADICATE HCV-RNA DETECTABLE IN PATIENTS NOT AFFECTED TO ANTIVIRAL TREATMENT THAT HAVE INFECTION OF CHRONIC HEPATITIS C
HUP0003131A2 (en) Polyethylene glycol-interferon alpha conjugates for therapy of infection
WO2006130553A3 (en) Hcv protease inhibitors
CA2245938A1 (en) Combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
MA27292A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEPATITIS C VIRUS
WO2004002999A8 (en) Modified 2' and 3' -nucleoside produgs for treating flaviridae infections
BR9911076A (en) Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis C
AR021226A1 (en) COMBINATORY THERAPY WITH RIBAVIRINA-INTERFERON ALFA TO ERADICATE DETECTABLE HCV-RNA IN THOSE PATIENTS WHO PRESENT INFECTION WITH CHRONIC HEPATITIS C
AR022116A1 (en) COMBINATION THERAPY FOR RHCAVIRINE INDUCTION HCV - INTERFERON ALFA
AR023541A1 (en) HCV COMBINATION THERAPY
JP2017514834A5 (en)
DE60125377D1 (en) TREATMENT OF HEPATITIS C WITH THYMOSINE, INTERFERON AND RIBAVIRIN
TH53874A3 (en) Combined HCV therapy by induction of ribavirin and pegilate-type interferon alpha.
ECSP993178A (en) COMBINATORY THERAPY WITH RIBARVIRINE-INTERFERON ALPHA TO ERADICATE HCV-DETECTABLE RNA IN THOSE PATIENTS WITH CHRONIC HEPATITIS C INFECTION
TH33755A (en) Combined therapy to eliminate detectable HCV-RNA in patients with chronic hepatitis C infection.
DE60121449D1 (en) TREATMENT OF HEPATITIS C WITH THYMOSINE AND PEGYLATED INTERFERON
TH87484A (en) PEG-IFN Alpha and Ribavirin for HBV Treatment
TH87484B (en) PEG-IFN Alpha and Ribavirin for HBV Treatment
TH46769A (en) HCV co-treatment

Legal Events

Date Code Title Description
FB Suspension of granting procedure